| Why Is Corvus Pharmaceuticals Stock Soaring On Friday? |
Corvus Pharmaceuticals, Inc. CRVS on Thursday released new interim data from the Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. |
benzinga.com |
2025-05-09 15:57:40 |
Czytaj oryginał (ang.) |
| Corvus Pharmaceuticals, Inc. (CRVS) Q1 2025 Earnings Call Transcript |
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Zack Kubow - Real Chemistry, Investor Relations Leiv Lea - Chief Financial Officer Richard Miller - Chief Executive Officer Conference Call Participants Aydin Huseynov - Ladenburg Graig Suvannavejh - Mizuho Securities Li Watsek - Cantor Jeff Jones - Oppenheimer Roger Song - Jefferies Sean Lee - H.C. Wainwright Operator Good afternoon, everyone. |
seekingalpha.com |
2025-05-09 03:06:04 |
Czytaj oryginał (ang.) |
| Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results |
Soquelitinib data from cohorts 1-3 of atopic dermatitis Phase 1 clinical trial demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 |
globenewswire.com |
2025-05-08 20:02:00 |
Czytaj oryginał (ang.) |
| Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis |
Data continue to demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 |
globenewswire.com |
2025-05-08 20:01:00 |
Czytaj oryginał (ang.) |
| Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025 |
Data from Cohorts 1-3 of trial to be presented in an oral session and poster at the Society for Investigative Dermatology (SID) 2025 Annual Meeting |
globenewswire.com |
2025-04-23 20:08:00 |
Czytaj oryginał (ang.) |
| Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors |
SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced today that Richard van den Broek, managing partner at HSMR Advisors, has been appointed to the Company's board of directors. Mr. van den Broek has more than 30 years of experience in the life sciences industry as an investor, biotechnology equity research analyst and board member. |
globenewswire.com |
2025-04-09 20:01:00 |
Czytaj oryginał (ang.) |
| Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials |
Corvus Pharmaceuticals' leading drug candidate is Soquelitinib, which has broad potential across PTCL, atopic dermatitis, and ALPS. Unfortunately, it seems Corvus' early AD data might have disappointed investors (at least initially). Still, Soquelitinib's promising Phase 3 PTCL trial results are due late 2026. Its PFS metrics might help it to differentiate from other standard chemotherapy treatments. |
seekingalpha.com |
2025-03-28 11:30:00 |
Czytaj oryginał (ang.) |
| Corvus Pharmaceuticals: Now At Cruising Altitude |
Corvus Pharmaceuticals' stock has experienced volatility due to mixed clinical data, particularly from their lead asset soquelitinib's Phase 1 trial in atopic dermatitis. The company has promising developments, including a Phase 2 trial for autoimmune lymphoproliferative syndrome and potential solid tumor trials, but current data is inconclusive. Significant shareholder activity, including warrant exercises, has impacted stock price and ownership dynamics, with potential future dilution if more shares are issued. |
seekingalpha.com |
2025-03-28 11:29:55 |
Czytaj oryginał (ang.) |
| Corvus Pharmaceuticals, Inc. (CRVS) Q4 2024 Earnings Call Transcript |
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q4 2024 Earnings Conference Call March 25, 2025 4:30 PM ET Company Participants Zack Kubow - Real Chemistry, IR Leiv Lea - CFO Richard Miller - CEO Conference Call Participants Jeff Jones - Oppenheimer Aydin Huseynov - Ladenburg Thalmann Cha Cha Yang - Jefferies Daniel Bronder - Cantor Sean Lee - H.C. Wainwright Operator Good afternoon, everyone. |
seekingalpha.com |
2025-03-25 21:58:14 |
Czytaj oryginał (ang.) |
| Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results |
Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Data From Cohorts 1-3 anticipated to be Presented in May Initial Results From First Two Cohorts Supports Safety and Efficacy with Oral Agent and Novel Mechanism of Action Registration Phase 3 Clinical Trial of Soquelitinib in Peripheral T Cell Lymphoma (PTCL) Enrolling with Multiple Clinical Sites Open Conference call today at 4:30 p.m. ET / 1:30 p.m. |
globenewswire.com |
2025-03-25 18:01:00 |
Czytaj oryginał (ang.) |
| Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma |
Data to be presented in oral session and poster at the 16th Annual T-Cell Lymphoma Forum Data to be presented in oral session and poster at the 16th Annual T-Cell Lymphoma Forum |
globenewswire.com |
2025-03-20 10:00:00 |
Czytaj oryginał (ang.) |
| Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference |
SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and participate in a fireside chat presentation at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference, which is being held virtually. The fireside chat will be on Thursday, March 27, 2025 at 12:00 pm ET. |
globenewswire.com |
2025-03-19 18:01:00 |
Czytaj oryginał (ang.) |
| Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 |
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT |
globenewswire.com |
2025-03-17 18:01:00 |
Czytaj oryginał (ang.) |
| Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) |
Trial for this rare genetic disease to be conducted by NIH/NIAID in partnership with Corvus ITK inhibition intended to address dysregulation of T cells that causes ALPS and has been shown to be effective at treating the disease in preclinical models BURLINGAME, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has initiated a Phase 2 clinical trial of soquelitinib for the treatment of patients with autoimmune lymphoproliferative syndrome (ALPS), a rare genetic disease. |
globenewswire.com |
2025-03-12 10:00:00 |
Czytaj oryginał (ang.) |
| Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference |
BURLINGAME, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, which is being held virtually. The presentation will be on Tuesday, February 11, 2025 at 9:20 am ET. |
globenewswire.com |
2025-02-04 10:00:00 |
Czytaj oryginał (ang.) |
| Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis |
Data continue to demonstrate a favorable safety and efficacy profile, including improvements in IGA 0 or 1 and EASI 75 scores compared to placebo Data continue to demonstrate a favorable safety and efficacy profile, including improvements in IGA 0 or 1 and EASI 75 scores compared to placebo |
globenewswire.com |
2025-01-13 09:30:00 |
Czytaj oryginał (ang.) |
| Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
BURLINGAME, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer, will conduct one-on-one meetings with investors and present a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference, which is being held in San Francisco from January 13-16, 2025. The Company's presentation will be on Wednesday, January 15 at 2:15 pm ET / 11:15 am PT. |
globenewswire.com |
2025-01-07 18:01:00 |
Czytaj oryginał (ang.) |
| Corvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor Targeting |
Positive results released from phase 1 study, using 100 mg twice daily oral dosing soquelitinib for the treatment of patients with Atopic Dermatitis; Several other cohorts testing higher dosing. The global atopic dermatitis market size is projected to reach $22.6 billion by 2031. Corvus is developing next-generation ITK inhibitors which are going to offer a more tailored approach to targeting specific immunological disorders. |
seekingalpha.com |
2024-12-18 15:36:04 |
Czytaj oryginał (ang.) |
| Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday? |
Corvus Pharmaceuticals, Inc. CRVS released interim data from a Phase 1 trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. |
benzinga.com |
2024-12-18 15:23:45 |
Czytaj oryginał (ang.) |
| Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session |
U.S. stock futures were lower this morning, with the Dow futures falling around 150 points on Tuesday. |
benzinga.com |
2024-12-18 10:42:16 |
Czytaj oryginał (ang.) |
| Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis |
Data from lowest dose level cohorts demonstrate a favorable safety and efficacy profile Data includes complete results from cohort 1 and initial results from cohort 2 Early exercise of common stock warrants from stockholder generates cash proceeds of approximately $12.7 million Company to host conference call and webcast today at 8:00 a.m. ET / 5:00 a.m. |
globenewswire.com |
2024-12-18 09:30:00 |
Czytaj oryginał (ang.) |
| Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024 |
Company to host conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT on Wednesday, December 18, 2024 Company to host conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT on Wednesday, December 18, 2024 |
globenewswire.com |
2024-12-17 18:01:00 |
Czytaj oryginał (ang.) |
| Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity |
Data published in peer-reviewed npj Drug Discovery, a Nature portfolio journal Data published in peer-reviewed npj Drug Discovery, a Nature portfolio journal |
globenewswire.com |
2024-12-04 18:05:00 |
Czytaj oryginał (ang.) |
| Corvus (CRVS) is on the Move, Here's Why the Trend Could be Sustainable |
Corvus (CRVS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. |
zacks.com |
2024-11-15 11:50:20 |
Czytaj oryginał (ang.) |
| Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis |
Adds to growing body of evidence supporting the potential of ITK inhibition as a novel therapeutic for the treatment of a wide range of immune diseases |
globenewswire.com |
2024-11-14 12:01:00 |
Czytaj oryginał (ang.) |
| Corvus Pharmaceuticals: The Market Likes The Story |
Today, we take a look at Corvus Pharmaceuticals, whose stock has rocketed from under $2 a share this summer to around ten bucks a share. The company is advancing a couple of intriguing candidates within its developmental pipeline and recently kicked of a pivotal Phase 3 registrational study. Can the rally continue as the market increasingly buys into the story around Corvus or is some profit taking on the horizon? |
seekingalpha.com |
2024-11-13 15:18:15 |
Czytaj oryginał (ang.) |
| Corvus Pharmaceuticals, Inc. (CRVS) Q3 2024 Earnings Call Transcript |
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Zack Kubow - Real Chemistry, IR Leiv Lea - Chief Financial Officer Richard Miller - Chief Executive Officer Conference Call Participants Li Watsek - Cantor Jiale Song - Jefferies Aydin Huseynov - Ladenburg Graig Suvannavejh - Mizuho Jeff Jones - Oppenheimer Operator Good afternoon, everyone, and thank you for standing by, and welcome to the Corvus Pharmaceuticals Third Quarter 2024 Business Update and Financial Results Conference Call. At this time participants are in a listen-only mode. |
seekingalpha.com |
2024-11-13 02:02:52 |
Czytaj oryginał (ang.) |
| Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results |
Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Enrolling Patients in Second Dosing Cohort Interim Data from Atopic Dermatitis Trial Expected to be Announced December 2024 Registration Phase 3 Clinical Trial of Soquelitinib in Peripheral T Cell Lymphoma (PTCL) Enrolling with Multiple Clinical Sites Open Conference call today at 4:30 p.m. ET / 1:30 p.m. |
globenewswire.com |
2024-11-12 18:01:00 |
Czytaj oryginał (ang.) |
| Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer |
Data presented in an oral session at the Society for Immunotherapy of Cancer 39th Annual Meeting, where it was selected as a top 100 abstract Data presented in an oral session at the Society for Immunotherapy of Cancer 39th Annual Meeting, where it was selected as a top 100 abstract |
globenewswire.com |
2024-11-09 15:40:00 |
Czytaj oryginał (ang.) |
| Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024 |
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT |
globenewswire.com |
2024-11-05 18:02:00 |
Czytaj oryginał (ang.) |
| Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug |
CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell lymphoma. |
zacks.com |
2024-09-11 15:51:10 |
Czytaj oryginał (ang.) |
| Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma |
Soquelitinib is a potential first-in-class ITK inhibitor with broad potential in cancer and immune diseases There are currently no fully approved agents for the treatment of relapsed PTCL and soquelitinib has been granted Orphan Drug Designation and Fast Track Designation by the FDA BURLINGAME, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it has initiated a registrational Phase 3 clinical trial of soquelitinib for patients with relapsed/refractory peripheral T-cell lymphoma (PTCL). |
globenewswire.com |
2024-09-10 12:30:00 |
Czytaj oryginał (ang.) |
| Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference |
BURLINGAME, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer, and Jeffrey Arcara, chief business officer, will conduct one-on-one meetings with investors and present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference, which is being held in New York from September 9-11, 2024. The Company's presentation will be on Tuesday, September 10 at 12:00pm ET. |
globenewswire.com |
2024-09-03 20:05:00 |
Czytaj oryginał (ang.) |
| Corvus Pharmaceuticals Eyes Phase 3 Trials: Soquelitinib's Promise In PTCL |
Corvus Pharmaceuticals' lead candidate, Soquelitinib, is advancing towards a Phase 3 trial for PTCL, set to begin in September 2024. Soquelitinib has shown a 26% Complete Response Rate [CRR] in early trials, more than double the current standard of care. The PTCL market, estimated at $500 million in the U.S., offers significant potential if Soquelitinib's Phase 3 trials are successful. |
seekingalpha.com |
2024-09-03 11:03:57 |
Czytaj oryginał (ang.) |
| Corvus Pharmaceuticals, Inc. (CRVS) Q2 2024 Earnings Call Transcript |
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Zack Kubow - Real Chemistry, IR Richard Miller - Chief Executive Officer Leiv Lea - Chief Financial Officer Jeff Arcara - Chief Business Officer Jim Rosenbaum - Senior Vice President, Research Ben Jones - Senior Vice President, Regulatory and Pharmaceutical Sciences Conference Call Participants Li Watsek - Cantor Roger Song - Jefferies Aydin Huseynov - Ladenberg Jeff Jones - Oppenheimer Graig Suvannavejh - Mizuho Operator Good afternoon, everyone, and thank you for standing by. Welcome to the Corvus Pharmaceuticals Second Quarter 2024 Business Update and Financial Results Conference Call. |
seekingalpha.com |
2024-08-10 02:22:05 |
Czytaj oryginał (ang.) |
| Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results |
Early Results from Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Demonstrate Clinical Activity and Corresponding Changes in Cytokine Levels Consistent with ITK Inhibition Mechanism of Action |
globenewswire.com |
2024-08-06 20:01:00 |
Czytaj oryginał (ang.) |
| Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) |
Soquelitinib registrational Phase 3 clinical trial in PTCL advancing toward initial enrollment in Q3 2024 Fast track designation underscores unmet need for patients with relapsed or refractory PTCL, an indication with poor overall outcomes and no approved drugs based on randomized trials BURLINGAME, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to soquelitinib for the treatment of adult patients with relapsed or refractory peripheral T cell lymphoma (PTCL) after at least two lines of systemic therapy. |
globenewswire.com |
2024-08-01 12:30:00 |
Czytaj oryginał (ang.) |